Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients.

@article{Zurawska2013OutcomesOH,
  title={Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients.},
  author={Urszula Zurawska and Danielle A. Baribeau and S Giilck and Charles Victor and Saurabh S. Gandhi and Ana Florescu and Sh Verma},
  journal={Current oncology},
  year={2013},
  volume={20 6},
  pages={e539-45}
}
UNLABELLED Breast cancer is heterogenous, with variable expression of the estrogen receptor (er), progesterone receptor (pr), and human epidermal growth factor receptor 2 (her2). Overexpression of her2 is generally considered a negative prognostic feature, but whether outcomes for her2-positive early breast cancer remain different from those for other… CONTINUE READING